Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
about
Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.A highly efficient and sensitive LC-MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study.Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice.Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer.Afatinib in squamous cell carcinoma of the head and neck.A tag-free collisionally induced fragmentation approach to detect drug-adducted proteins by mass spectrometry.Afatinib Decreases P-Glycoprotein Expression to Promote Adriamycin Toxicity of A549T Cells.Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib.
P2860
Q33653707-C65C77E0-D936-4703-9543-44963F77878DQ35829430-6DB3918D-CF22-41AE-9C25-09C83AB739BAQ35873072-A939AF3F-2762-4EA8-9F14-EE04CEC48C8BQ37642541-9DEC11A7-908D-446D-9F43-1CAF110A55F8Q37650711-2CDA27E7-B03D-4548-8494-998358F41E5AQ38594474-28D36DDD-30DB-4F76-BFD9-D5BCB093ECBFQ38829891-1A30AA7D-B47E-43FC-893A-B0B4C4DDEF8CQ48119987-1E63C028-042B-4605-915D-86B799D7CF18Q48314681-F683A3EC-5979-4ABE-BAF2-BADE207C5784Q54267525-C03158DB-9485-4F26-BB18-1896FC5A00F6
P2860
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
@ast
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
@en
type
label
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
@ast
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
@en
prefLabel
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
@ast
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
@en
P2093
P2860
P1476
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
@en
P2093
Atef Halabi
David Schnell
Dietmar Gansser
Holger Fuchs
Marc Petersen-Sylla
Martina Uttenreuther-Fischer
Peter Stopfer
Rainer-Georg Goeldner
Rüdiger Koenen
Susanne Buschke
P2860
P2888
P304
P356
10.1007/S00280-014-2484-Y
P577
2014-06-07T00:00:00Z
P5875
P6179
1028497145